Goldman Sachs
PTGX icon

Goldman Sachs’s Protagonist Therapeutics PTGX Stock Holding History

Goldman Sachs’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82.1M Sell
778,945
-182,204
-19% -$16.1M 0.01% 1184
2025
Q4 		$83.9M Buy
961,149
+179,438
+23% +$14.7M 0.01% 1119
2025
Q3 		$51.9M Buy
781,711
+4,404
+0.6% +$250K 0.01% 1388
2025
Q2 		$43M Buy
777,307
+221,756
+40% +$10.6M 0.01% 1441
2025
Q1 		$26.9M Sell
555,551
-203,139
-27% -$8.51M ﹤0.01% 1747
2024
Q4 		$29.3M Sell
758,690
-63,166
-8% -$2.75M ﹤0.01% 1765
2024
Q3 		$37M Buy
821,856
+231,095
+39% +$9.34M 0.01% 1502
2024
Q2 		$20.5M Buy
590,761
+65,721
+13% +$1.92M ﹤0.01% 1869
2024
Q1 		$15.2M Buy
525,040
+9,820
+2% +$267K ﹤0.01% 2079
2023
Q4 		$11.8M Buy
515,220
+48,017
+10% +$840K ﹤0.01% 2376
2023
Q3 		$7.79M Sell
467,203
-92,007
-16% -$1.79M ﹤0.01% 2603
2023
Q2 		$15.4M Buy
559,210
+99,760
+22% +$2.5M ﹤0.01% 2071
2023
Q1 		$10.6M Sell
459,450
-157,274
-26% -$2.64M ﹤0.01% 2363
2022
Q4 		$6.73M Sell
616,724
-140,355
-19% -$1.18M ﹤0.01% 2926
2022
Q3 		$6.38M Buy
757,079
+125,163
+20% +$1.18M ﹤0.01% 2919
2022
Q2 		$5M Buy
631,916
+285,557
+82% +$3.45M ﹤0.01% 3131
2022
Q1 		$8.2M Buy
346,359
+222,730
+180% +$6.28M ﹤0.01% 2888
2021
Q4 		$4.23M Sell
123,629
-299,566
-71% -$9.47M ﹤0.01% 3572
2021
Q3 		$7.5M Buy
423,195
+31,252
+8% +$1.33M ﹤0.01% 2998
2021
Q2 		$17.6M Sell
391,943
-22,191
-5% -$732K ﹤0.01% 2166
2021
Q1 		$10.7M Sell
414,134
-137,653
-25% -$3.48M ﹤0.01% 2503
2020
Q4 		$11.1M Buy
551,787
+329,707
+148% +$7.1M ﹤0.01% 2371
2020
Q3 		$4.34M Sell
222,080
-307,968
-58% -$5.78M ﹤0.01% 3021
2020
Q2 		$9.36M Buy
530,048
+466,347
+732% +$5.85M ﹤0.01% 2327
2020
Q1 		$449K Buy
63,701
+43,562
+216% +$326K ﹤0.01% 4279
2019
Q4 		$142K Sell
20,139
-136,822
-87% -$1.36M ﹤0.01% 4984
2019
Q3 		$1.89M Buy
156,961
+132,900
+552% +$1.67M ﹤0.01% 3574
2019
Q2 		$291K Sell
24,061
-76,931
-76% -$851K ﹤0.01% 4633
2019
Q1 		$1.27M Buy
100,992
+72,993
+261% +$644K ﹤0.01% 3923
2018
Q4 		$188K Sell
27,999
-11,370
-29% -$90.2K ﹤0.01% 4843
2018
Q3 		$405K Sell
39,369
-43,495
-52% -$374K ﹤0.01% 4530
2018
Q2 		$557K Buy
82,864
+51,795
+167% +$398K ﹤0.01% 4445
2018
Q1 		$267K Buy
31,069
+1,506
+5% +$28.4K ﹤0.01% 4846
2017
Q4 		$615K Buy
+29,563
New +$524K ﹤0.01% 4666
2016
Q4 		– Sell
-13,340
Closed -$282K – 7041
2016
Q3 		$282K Buy
+13,340
New +$182K ﹤0.01% 5528

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Goldman Sachs's PTGX Position: Q1 2026 in Review

Goldman Sachs reduced its Protagonist Therapeutics (PTGX) stake by 19% in Q1 2026, selling an estimated $16.1M and leaving 778,945 shares worth $82.1M. The position accounts for 0.01% of the portfolio, ranked #1184.

Goldman Sachs first reported a position in PTGX in Q3 2016 and has held it in 35 quarters since. The position peaked at $83.9M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Goldman Sachs held 778,945 shares of Protagonist Therapeutics worth $82.1M as of Q1 2026.
  • Goldman Sachs sold 182,204 Protagonist Therapeutics shares in Q1 2026, an estimated $16.1M.
  • Protagonist Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1184 holding.
  • Goldman Sachs first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 35 quarters since.
  • Goldman Sachs's Protagonist Therapeutics position peaked at $83.9M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.